The nonsense in our genes

One in 200 genes superfluous?

The nonsense in our genes

 

One in 200 of our human genes can be inactivated with no detectable effect on our health. A study by Wellcome Trust Sanger Institute scientists raises new questions about the effects of gene loss on our wellbeing and evolution.

nonsense-snps_300.jpg
Frequency of nonsense-SNPs in the study sample, plotted on a log scale. Each vertical bar represents one SNP. Green, proportion of individuals with two copies of the normal allele; purple, proportion with one normal and one disrupting allele; orange, proportion with two copies of the disrupting allele. The plot shows that almost 60 per cent of SNPs could be found as homozygous truncated versions, resulting in gene inactivity.

The study, published today in The American Journal of Human Genetics, explores single letter changes in our genetic code that affect the ability of genes to produce proteins. The researchers' findings suggest that such mutations, while sometimes harmful, generally have little consequence for the individual and may occasionally even be beneficial in evolutionary terms.

The team studied variations in the genetic code of more than 1000 people from around the world. They focused their work on single-letter changes (called SNPs) that disrupt proteins, leading to versions that are either shorter or completely absent. One might intuitively expect that such a change - called a nonsense-SNP - would be harmful to the person.

"We knew that these mutations existed and that many have been associated with genetic diseases, but we were amazed to find that they were so common in the general population. We found that 167 genes could be inactivated by nonsense mutations, and that individuals carry on average at least 46 such variations. For 99 of the genes, both copies could be lost in adults living a normal existence."

Bryndis Yngvadottir, lead author on the study, from the Wellcome Trust Sanger Institute

Human DNA contains approximately 20,000 genes: the total of 99 genes with nonsense-SNPs means that at least one in 200 genes is dispensable. Some harmful nonsense-SNPs were also present among the 167 genes studied: eight are listed in the Human Gene Mutation Database which catalogues disease-causing mutations.

While the researchers found that inactivating genes was, on the whole, slightly harmful, there were exceptions. In East Asia, but not in other places, it seems to have been advantageous to lose the MAGEE2 gene.

"There is a theory that 'less is more' where genes are concerned and we already knew of a couple of examples of advantageous gene loss. But this is the first large-scale investigation of its significance for recent human evolution."

"The MAGEE2 gene is an interesting new example, although we have absolutely no idea what this gene does, or why some people are better off without it. However, our study suggests that overall, gene loss has not been a major evolutionary force: our genome does not seem to be in a hurry to get rid of these 'superfluous' genes."

Chris Tyler-Smith, coordinator the study, from the Wellcome Trust Sanger Institute

"Certain types of genes tend to be lost preferentially. We found the biggest decrease in the genes that contribute to our sense of smell. Perhaps early humans didn't like smelly partners, and so when humans started to live together in big groups it helped their chances of finding true love if they couldn't smell their partner too strongly."

Bryndis Yngvadottir, Sanger Institute

Genetic variation in nonsense-SNP numbers was significant: participants in the survey had between 29 and 65 of these mutations each and varied on average by 24 genes as a consequence. Eighteen of the 169 nonsense-SNPs investigated are also present in the Craig Venter genome published last year.

Notes to Editors
Publications
  • A genome-wide survey of the prevalence and evolutionary forces acting on human nonsense SNPs.

    Yngvadottir B, Xue Y, Searle S, Hunt S, Delgado M et al.

    American journal of human genetics 2009;84;2;224-34

Funding

This work was funded by the Wellcome Trust.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Appointments and changes to the Genome Research Limited Board
At the GRL Board meeting on 2 December 2019, David Willetts announced his intention to step down as Chair because of his extensive commitments across the academic and science sectors. Wellcome's Director, Jeremy Farrar, will take over the Chair of GRL Board from 1 January 2020.
Researchers identify new possibilities for the treatment of inflammatory bowel disease
Two molecular pathways found to be integral to maintaining balance in the digestive system
Root of childhood kidney cancer discovered
Pre-cancerous signatures found in healthy tissue point the way towards new treatment options